Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

612
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
612
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

5.0K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K
The Tumor Microenvironment02:17

The Tumor Microenvironment

6.7K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The CARM1 epigenetic enzyme inhibits cross-presenting dendritic cell function in cancer immunity.

Science (New York, N.Y.)·2026
Same author

Integrating cytological images and spatial transcriptomics for cell segmentation with DISSECT.

Nature computational science·2026
Same author

Discovery of Tcf7 regulators with clonally-resolved CRISPR screens identifies Trim28 as a mediator of CD8 T cell differentiation in tumors.

bioRxiv : the preprint server for biology·2026
Same author

Inhibition of salt-inducible kinases reprograms T cells and antitumor immunity in ovarian cancer.

Nature immunology·2026
Same author

Carboplatin with or without nivolumab in metastatic triple-negative breast cancer: a randomized phase II trial.

Nature communications·2026
Same author

Arid3b suppresses CD8 + T cell infiltration and function in microsatellite-stable colorectal cancer via Runx3.

Nature communications·2026

Related Experiment Video

Updated: Aug 9, 2025

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.7K

Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell-Secreted Cytokines.

Yoshinaga Ito1,2,3, Deng Pan1,2, Wubing Zhang4

  • 1Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Cancer Discovery
|February 22, 2023
PubMed
Summary

Targeting TNF signaling and autophagy pathways enables T cells to eliminate MHC-I-deficient tumor cells, overcoming a key barrier in cancer immunotherapy.

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

566
Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity
06:16

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity

Published on: December 7, 2019

12.8K

Related Experiment Videos

Last Updated: Aug 9, 2025

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.7K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

566
Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity
06:16

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity

Published on: December 7, 2019

12.8K

Area of Science:

  • Immunology
  • Cancer Biology
  • Molecular Biology

Background:

  • Tumor heterogeneity poses a significant challenge to effective cancer therapy, particularly immunotherapy.
  • The loss of MHC class I (MHC-I) expression in tumor cells allows them to evade T cell-mediated killing.
  • Identifying alternative mechanisms to eliminate MHC-I-deficient tumor cells is crucial for improving treatment outcomes.

Purpose of the Study:

  • To discover novel pathways for T cell-mediated killing of MHC-I-deficient tumor cells.
  • To investigate the role of autophagy and TNF signaling in T cell recognition and killing of resistant tumor cells.
  • To develop therapeutic strategies to overcome tumor resistance in immunotherapy.

Main Methods:

  • Genome-scale screening to identify pathways involved in T cell killing of MHC-I-deficient cells.
  • Genetic and pharmacologic targeting of the TNF signaling (RNF31) and autophagy (ATG5) pathways.
  • Analysis of T cell-derived cytokine-induced apoptosis in tumor cells.
  • Assessment of antigen cross-presentation by dendritic cells and T cell infiltration.
  • Evaluation of tumor control in models with substantial MHC-I-deficient cell populations.

Main Results:

  • Autophagy and TNF signaling pathways were identified as critical for T cell-mediated killing of MHC-I-deficient tumor cells.
  • Inactivation of RNF31 (TNF signaling) and ATG5 (autophagy) sensitized MHC-I-deficient tumor cells to apoptosis induced by T cell cytokines.
  • Inhibition of autophagy enhanced the pro-apoptotic effects of cytokines on tumor cells.
  • Apoptotic MHC-I-deficient tumor cells facilitated efficient cross-presentation of antigens by dendritic cells, leading to increased infiltration of IFNγ- and TNFα-producing T cells.
  • Combined targeting of TNF signaling and autophagy pathways enabled T cell-mediated control of tumors containing MHC-I-deficient cells.

Conclusions:

  • Targeting TNF signaling and autophagy pathways represents a promising strategy to eliminate MHC-I-deficient tumor cells, a major hurdle in cancer immunotherapy.
  • This dual-targeting approach can overcome tumor resistance mediated by MHC-I loss.
  • The findings provide a foundation for developing novel immunotherapeutic interventions against heterogeneous tumors.